BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24840578)

  • 21. Molecular and clinicopathologic features of gliomas harboring NTRK fusions.
    Torre M; Vasudevaraja V; Serrano J; DeLorenzo M; Malinowski S; Blandin AF; Pages M; Ligon AH; Dong F; Meredith DM; Nasrallah MP; Horbinski C; Dahiya S; Ligon KL; Santi M; Ramkissoon SH; Filbin MG; Snuderl M; Alexandrescu S
    Acta Neuropathol Commun; 2020 Jul; 8(1):107. PubMed ID: 32665022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A kinase-deficient NTRK2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways.
    Pattwell SS; Arora S; Cimino PJ; Ozawa T; Szulzewsky F; Hoellerbauer P; Bonifert T; Hoffstrom BG; Boiani NE; Bolouri H; Correnti CE; Oldrini B; Silber JR; Squatrito M; Paddison PJ; Holland EC
    Nat Commun; 2020 Jun; 11(1):2977. PubMed ID: 32532995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NTRK point mutations and their functional consequences.
    Rogers C; Morrissette JJD; Sussman RT
    Cancer Genet; 2022 Apr; 262-263():5-15. PubMed ID: 34972036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451
    Tatematsu T; Sasaki H; Shimizu S; Okuda K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Brown J; Fujii Y
    Mol Clin Oncol; 2014 Sep; 2(5):725-730. PubMed ID: 25054037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours.
    Li Y; Wei C; Wang W; Li Q; Wang ZC
    J Pathol Clin Res; 2023 Mar; 9(2):89-99. PubMed ID: 36533776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NTRK-rearranged Cervical Sarcoma: Expanding the Clinicopathologic Spectrum.
    Hodgson A; Pun C; Djordjevic B; Turashvili G
    Int J Gynecol Pathol; 2021 Jan; 40(1):73-77. PubMed ID: 32044823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
    Schliesser MG; Claus R; Hielscher T; Grimm C; Weichenhan D; Blaes J; Wiestler B; Hau P; Schramm J; Sahm F; Weiß EK; Weiler M; Baer C; Schmidt-Graf F; Schackert G; Westphal M; Hertenstein A; Roth P; Galldiks N; Hartmann C; Pietsch T; Felsberg J; Reifenberger G; Sabel MC; Winkler F; von Deimling A; Meisner C; Vajkoczy P; Platten M; Weller M; Plass C; Wick W
    Oncotarget; 2016 Dec; 7(50):82028-82045. PubMed ID: 27880937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying patients with NTRK fusion cancer.
    Solomon JP; Benayed R; Hechtman JF; Ladanyi M
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colonic Adenocarcinomas Harboring NTRK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature.
    Lasota J; Chłopek M; Lamoureux J; Christiansen J; Kowalik A; Wasąg B; Felisiak-Gołąbek A; Agaimy A; Biernat W; Canzonieri V; Centonze G; Chmielik E; Daum O; Dubová M; Dziuba I; Goertz S; Góźdź S; Guttmejer-Nasierowska A; Haglund C; Hałoń A; Hartmann A; Inaguma S; Iżycka-Świeszewska E; Kaczorowski M; Kita P; Kołos M; Kopczyński J; Michal M; Milione M; Okoń K; Pęksa R; Pyzlak M; Ristimäki A; Ryś J; Szostak B; Szpor J; Szumiło J; Teresiński L; Waloszczyk P; Wejman J; Wesołowski W; Miettinen M
    Am J Surg Pathol; 2020 Feb; 44(2):162-173. PubMed ID: 31567189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF; Demetri GD
    Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Site specific hypermethylation of CpGs in Connexin genes 30, 26 and 43 in different grades of glioma and attenuated levels of their mRNAs.
    J J; Vanisree AJ; Ravisankar S; K R
    Int J Neurosci; 2019 Mar; 129(3):273-282. PubMed ID: 30280947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NTRK1 and NTRK2 receptors facilitate follicle assembly and early follicular development in the mouse ovary.
    Kerr B; Garcia-Rudaz C; Dorfman M; Paredes A; Ojeda SR
    Reproduction; 2009 Jul; 138(1):131-40. PubMed ID: 19357131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurotrophin receptors expression and JNK pathway activation in human astrocytomas.
    Assimakopoulou M; Kondyli M; Gatzounis G; Maraziotis T; Varakis J
    BMC Cancer; 2007 Oct; 7():202. PubMed ID: 17971243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low expression of insulin-like growth factor binding protein 7 associated with poor prognosis in human glioma.
    Tian X; Zhang L; Sun L; Xue Y; Xie S
    J Int Med Res; 2014 Jun; 42(3):651-8. PubMed ID: 24743871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-expression of midkine and pleiotrophin predicts poor survival in human glioma.
    Ma J; Lang B; Wang X; Wang L; Dong Y; Hu H
    J Clin Neurosci; 2014 Nov; 21(11):1885-90. PubMed ID: 25001988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
    Wu X; Wu F; Xu D; Zhang T
    J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.